142 related articles for article (PubMed ID: 38227942)
1. Venous Thromboembolic Risk of Estradiol Valerate-Dienogest Compared with Ethinyl Estradiol-Levonorgestrel Combined Oral Contraceptives.
Bauerfeind A; von Stockum S; Boehnke T; Heinemann K
Obstet Gynecol; 2024 Mar; 143(3):431-434. PubMed ID: 38227942
[TBL] [Abstract][Full Text] [Related]
2. Impact of estrogen type on cardiovascular safety of combined oral contraceptives.
Dinger J; Do Minh T; Heinemann K
Contraception; 2016 Oct; 94(4):328-39. PubMed ID: 27343748
[TBL] [Abstract][Full Text] [Related]
3. Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel.
Klipping C; Duijkers I; Parke S; Mellinger U; Serrani M; Junge W
Drugs R D; 2011; 11(2):159-70. PubMed ID: 21679006
[TBL] [Abstract][Full Text] [Related]
4. Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction.
Davis SR; Bitzer J; Giraldi A; Palacios S; Parke S; Serrani M; Mellinger U; Nappi RE
J Sex Med; 2013 Dec; 10(12):3069-79. PubMed ID: 24034466
[TBL] [Abstract][Full Text] [Related]
5. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study.
Dinger J; Assmann A; Möhner S; Minh TD
J Fam Plann Reprod Health Care; 2010 Jul; 36(3):123-9. PubMed ID: 20659364
[TBL] [Abstract][Full Text] [Related]
6. Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: A literature review.
Lete I; Chabbert-Buffet N; Jamin C; Lello S; Lobo P; Nappi RE; Pintiaux A
Eur J Contracept Reprod Health Care; 2015; 20(5):329-43. PubMed ID: 26007631
[TBL] [Abstract][Full Text] [Related]
7. Association of Risk for Venous Thromboembolism With Use of Low-Dose Extended- and Continuous-Cycle Combined Oral Contraceptives: A Safety Study Using the Sentinel Distributed Database.
Li J; Panucci G; Moeny D; Liu W; Maro JC; Toh S; Huang TY
JAMA Intern Med; 2018 Nov; 178(11):1482-1488. PubMed ID: 30285041
[TBL] [Abstract][Full Text] [Related]
8. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel.
Ahrendt HJ; Makalová D; Parke S; Mellinger U; Mansour D
Contraception; 2009 Nov; 80(5):436-44. PubMed ID: 19835717
[TBL] [Abstract][Full Text] [Related]
9. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study.
Junge W; Mellinger U; Parke S; Serrani M
Clin Drug Investig; 2011; 31(8):573-584. PubMed ID: 21721593
[TBL] [Abstract][Full Text] [Related]
10. Estradiol valerate/dienogest: a novel oral contraceptive.
Whalen KL; Rose R
Ann Pharmacother; 2011 Oct; 45(10):1256-61. PubMed ID: 21917554
[TBL] [Abstract][Full Text] [Related]
11. Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17β-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism.
Reed S; Koro C; DiBello J; Becker K; Bauerfeind A; Franke C; Heinemann K
Eur J Contracept Reprod Health Care; 2021 Dec; 26(6):439-446. PubMed ID: 34644228
[TBL] [Abstract][Full Text] [Related]
12. Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol?
Bird ST; Delaney JA; Etminan M; Brophy JM; Hartzema AG
J Thromb Haemost; 2013 Jun; 11(6):1059-68. PubMed ID: 23574590
[TBL] [Abstract][Full Text] [Related]
13. Thrombotic risks of oral contraceptives.
Rott H
Curr Opin Obstet Gynecol; 2012 Aug; 24(4):235-40. PubMed ID: 22729096
[TBL] [Abstract][Full Text] [Related]
14. Estradiol valerate/dienogest: a novel combined oral contraceptive.
Borgelt LM; Martell CW
Clin Ther; 2012 Jan; 34(1):37-55. PubMed ID: 22169052
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception.
Dragoman MV; Tepper NK; Fu R; Curtis KM; Chou R; Gaffield ME
Int J Gynaecol Obstet; 2018 Jun; 141(3):287-294. PubMed ID: 29388678
[TBL] [Abstract][Full Text] [Related]
16. Use of combined oral contraceptives and risk of venous thromboembolism in young women: a nested case-control analysis using German claims data.
Schink T; Princk C; Braitmaier M; Haug U
BJOG; 2022 Dec; 129(13):2107-2116. PubMed ID: 35876787
[TBL] [Abstract][Full Text] [Related]
17. Is the multinational, surveillance PRO-E2 study informative for all countries? The Italian data on VTE and contraceptive effectiveness.
Fruzzetti F; Cagnacci A; Boolell M; Di Carlo C; Bruni V
Eur J Contracept Reprod Health Care; 2024 Feb; 29(1):1-7. PubMed ID: 38085301
[TBL] [Abstract][Full Text] [Related]
18. Drospirenone-Containing Oral Contraceptive Pills and the Risk of Venous Thromboembolism: An Assessment of Risk in First-Time Users and Restarters.
Larivée N; Suissa S; Coulombe J; Tagalakis V; Filion KB
Drug Saf; 2017 Jul; 40(7):583-596. PubMed ID: 28382493
[TBL] [Abstract][Full Text] [Related]
19. Comparison of estrogenic components used for hormonal contraception.
Stanczyk FZ; Winer SA; Foidart JM; Archer DF
Contraception; 2024 Feb; 130():110310. PubMed ID: 37863464
[TBL] [Abstract][Full Text] [Related]
20. Estradiol valerate/dienogest: in oral contraception.
Hoy SM; Scott LJ
Drugs; 2009 Aug; 69(12):1635-46. PubMed ID: 19678714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
